Michael D. Bright

London, ENG SM25NG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones.

Discovery of an In Vivo Chemical Probe for BCL6 Inhibition by Optimization of Tricyclic Quinolinones.

Journal: Journal of medicinal chemistry

Published: April 07, 2023

Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.

Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.

Journal: Journal of medicinal chemistry

Published: June 03, 2022

Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo.

Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo.

Journal: Journal of medicinal chemistry

Published: June 02, 2022

Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket.

Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket.

Journal: Journal of medicinal chemistry

Published: November 30, 2021

A Safe Approach to Percutaneous Tracheostomy for COVID-19 Patients in Intensive Care.

A Safe Approach to Percutaneous Tracheostomy for COVID-19 Patients in Intensive Care.

Journal: Cureus

Published: May 31, 2021

Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders.

Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders.

Journal: Journal of medicinal chemistry

Published: April 11, 2020

An RNAi screen of Rho signalling networks identifies RhoH as a regulator of Rac1 in prostate cancer cell migration.

An RNAi screen of Rho signalling networks identifies RhoH as a regulator of Rac1 in prostate cancer cell migration.

Journal: BMC biology

Published: November 13, 2017

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling.

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling.

Journal: Cellular signalling

Published: August 24, 2017

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 20, 2017

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Journal: Blood cancer journal

Published: February 12, 2017

Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress.

Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress.

Journal: Molecular and cellular biology

Published: January 09, 2015

Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1α.

Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1α.

Journal: BMC biochemistry

Published: September 05, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026